|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the number of patients that developed typical (Mycobacterium tuberculosis [MTB]) and atypical mycobacterial infections (AMI) while on treatment with ruxolitinib by utilizing the United States Food and Drug Administration (FDA) adverse events reporting system (FAERS).
|
31699655 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, some lncRNAs, such as MEG3, MT1JP, and H19, play a tumor suppressive role.
|
31202519 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggested that lncRNA MT1JP acts a tumor suppressor gene in bladder cancer progression, considering MT1JP as a new therapeutic target in bladder cancer.
|
30786017 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our rescue experiments showed that the tumor suppressive and cisplatin-sensitizing functions of MT1JP were mediated by negative regulation of miR-24-3p.
|
30787983 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite efforts to promote bi-directional screening of TB and DM, the uptake of TB testing among pre-diabetes and diabetes cases was only 4.7%, while the uptake of DM testing among MTB positive cases was 21.8%.
|
30841929 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The lipolytic protein LipU was conserved in mycobacterium sp. including M. tuberculosis (MTB LipU) and M. leprae (MLP LipU).
|
29557724 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated several novel methods including Xpert Mycobacterium tuberculosis/rifampicin (Xpert MTB/RIF) technology, quantitative fluorescence Polymerase Chain Reaction (qPCR) and High-Resolution Melting Curve (HRMC) in the diagnosis of superficial lymph node TB.
|
31333119 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of vaccine antigens (Ags) by considering Mtb genetic diversity is crucial for the development of improved TB vaccine.
|
30753099 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The binding affinity of all the designed compounds for HIV-RT and Mycobacterium tuberculosis Enol Reductase (MTB InhA) was gauged by molecular docking studies which revealed crucial thermodynamic interactions governing their binding.
|
30574853 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of two alternative methods of pooling sputum prior to testing for tuberculosis with genexpert MTB/RIF.
|
31029099 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, two high-throughput TB PCR assays with combined antimicrobial resistance detection, Anyplex™ II MTB/MDR (Seegene) and RealTime MTB + RealTime MTB RIF/INH Resistance (Abbott Molecular), were evaluated for routine use in a clinical setting of low population and low TB prevalence in Finland.
|
30901113 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance.
|
30902741 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ability of Xpert MTB/RIF assay for rapid and simultaneous detection of MTB and RIF resistance in comparison with culture makes it a useful diagnostic tool in skeletal TB.
|
30880713 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive results of molecular tests including MTB polymerase chain reaction and/or Xpert TB/RIF were only obtained in the not-missed TB group (54/106, 54%).
|
30775402 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
IP-10 levels in plasma, DPS and DBS samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, were quantified by an enzyme-linked immunosorbent assay.
|
30846768 |
2019 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have confirmed that pooling of two sputum specimens for testing in a single cartridge is a valid method of reducing the number of cartridges required when using Xpert MTB to detect pulmonary tuberculosis.
|
31029099 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MT1JP has recently been reported to be differentially expressed and act as a tumor suppressor in different tumors, with its mechanisms not fully understood in GC.
|
29742512 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas.
|
29408377 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated that MT1JP was a tumor suppressor by negatively modulating the activity of the Wnt/β-catenin signaling pathway in the development of retinoblastoma and might function as a prognostic biomarker and therapeutic target.
|
30024609 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatases A and B (PtpA and PtpB) have been recognized as potential molecular targets for the development of new therapeutic strategies against tuberculosis (TB).
|
29275228 |
2018 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlation of results of polymerase chain reaction for Mycobacterium tuberculosis (MTB PCR) with clinical features and treatment response in tubercular uveitis.
|
28665743 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In efforts to discover Mycobacterium tuberculosis (Mtb) biomarkers we identified by mass spectroscopy a unique 21-mer Mtb peptide sequence (VVLGLTVPGGVELLPGVALPR) present in the urines of TB patients from Zimbabwe.
|
29306028 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations AR allergic rhinitis AM alveolar macrophage ATG autophagy-related CF cystic fibrosis CFTR cystic fibrosis transmembrane conductance regulator COPD chronic obstructive pulmonary disease CS cigarette smoke CSE cigarette smoke extract DC dendritic cell IH intermittent hypoxia IPF idiopathic pulmonary fibrosis ILD interstitial lung disease MAP1LC3B microtubule associated protein 1 light chain 3 beta MTB Mycobacterium tuberculosis MTOR mechanistic target of rapamycin kinase NET neutrophil extracellular traps OSA obstructive sleep apnea PAH pulmonary arterial hypertension PH pulmonary hypertension ROS reactive oxygen species TGFB1 transforming growth factor beta 1 TNF tumor necrosis factor.
|
29130366 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
World Health Organization (WHO) recommended Lateral Flow urine LipoArabinoMannan assay (LF-LAM) in immunocompromised patients; in 2010 WHO endorsed the use of Xpert Mycobacterium Tuberculosis/Rifampicin (MTB/RIF) test for rapid TB diagnosis but the assay is not used as screening test in all HIV+ patients irrespectively of symptoms due to cost and logistical barriers.
|
30024890 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to MTB culture, overall sensitivity and specificity of TB-LAMP were 55.4% (95 CI 44.1-66.3) and 98.0% (95 CI 94.3-99.6) respectively.
|
29466946 |
2018 |